Metastatic Melanoma Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

Pages: 946 Published: June 28, 2022 Report Code: GDHC6891CTIDB

Metastatic Melanoma clinical trials market research report provides top line data relating to the clinical trials on Metastatic Melanoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials.

Key Regions In The Metastatic Melanoma Clinical Trials Market

The key regions in the metastatic melanoma clinical trials market are North America, Europe, Asia-Pacific, Middle East and Africa, and South and Central America. North America has the highest number of clinical trials.

Metastatic melanoma clinical trials market in Asia-Pacific

Australia, China, South Korea, Japan, and New Zealand are the key countries in the Asia-Pacific region in the metastatic melanoma clinical trials market. Among them Australia has the highest number of clinical trials.

Metastatic melanoma clinical trials market in Europe

Germany, France, Italy, the UK, and Spain are the key countries in Europe in the metastatic melanoma clinical trials market. Among them Germany has the highest number of clinical trials in the metastatic melanoma clinical trials market.

Metastatic melanoma clinical trials market in Middle East and Africa

Israel, South Africa, and Egypt are the key countries in Middle east and Africa in the metastatic melanoma clinical trials market. Israel has the highest number of clinical trials.

Metastatic melanoma clinical trials market in North America

The US, Canada, and Mexico are the key countries in North America in the metastatic melanoma clinical trials market. Among them the US has the highest number of clinical trials.

Metastatic melanoma clinical trials market in Central and South America

Brazil, Argentina, Chile, Colombia, and Peru are the key countries in Central and South America in the metastatic melanoma clinical trials market. Among them Brazil has the highest number of clinical trials.

Metastatic Melanoma Clinical Trials Market, By Regions

Metastatic Melanoma Clinical Trials Market, By Regions

For more regional insights, download a free report sample

G7 Countries Landscape In The Metastatic Melanoma Clinical Trials Market

The G7 countries include the US, Germany, France, Italy, Canada, the UK, and Japan. The US has the highest number of clinical trials of metastatic melanoma.

Metastatic Melanoma Clinical Trials Market, by G7 Countries

Metastatic Melanoma Clinical Trials Market, by G7 Countries

For more G7 country insights, download a free report sample

E7 Countries Landscape In The Metastatic Melanoma Clinical Trials Market

The E7 countries include China, Russia, Brazil, Mexico, Turkey, Indonesia, and India. Among them China has the highest number of clinical trials.

Metastatic Melanoma Clinical Trials Market, by E7 Countries

Metastatic Melanoma Clinical Trials Market, by E7 Countries

For more E7 country insights, download a free report sample

Key Sponsors in The Metastatic Melanoma Clinical Trials Market

  • Bristol-Myers Squibb Co
  • Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • GSK plc
  • AstraZeneca Plc
  • Incyte Corp
  • Amgen Inc
  • Eli Lilly and Co

Metastatic Melanoma Clinical Trials Market, by Sponsors

Metastatic Melanoma Clinical Trials Market, by Sponsors

To know more about sponsors, download a free report sample

Market report overview

Key regions North America, Europe, Asia-Pacific, Middle East and Africa, and South and Central America
Key sponsors Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, Merck & Co Inc, Novartis AG, Pfizer Inc, GSK plc, AstraZeneca Plc, Incyte Corp, Amgen Inc, and Eli Lilly and Co

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
  • Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
  • Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Key Players

  • Bristol-Myers Squibb Co

    F. Hoffmann-La Roche Ltd

    Merck & Co Inc

    Novartis AG

    Pfizer Inc

    GSK plc

    AstraZeneca Plc

    Incyte Corp

    Amgen Inc

    Eli Lilly and Co

Table of Contents

Table of Contents

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Clinical Trials by G7 Countries: Proportion of Metastatic Melanoma to Oncology Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Metastatic Melanoma to Oncology Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Metastatic Melanoma Therapeutics Clinical Trials

Prominent Drugs

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About GlobalData

Contact Us

Disclaimer

Source

List of Tables

List of Tables

Metastatic Melanoma Therapeutics, Global, Clinical Trials by Region, 2022*

Metastatic Melanoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*

Metastatic Melanoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, North America, Top Countries, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2022*

Proportion of Metastatic Melanoma to Oncology Clinical Trials, G7 Countries (%), 2022*

Metastatic Melanoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*

Metastatic Melanoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*

Proportion of Metastatic Melanoma to Oncology Clinical Trials, E7 Countries (%), 2022*

Metastatic Melanoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*

Metastatic Melanoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*

Metastatic Melanoma Therapeutics, Global, Clinical Trials by Phase, 2022*

Metastatic Melanoma Therapeutics, Global, Clinical Trials In Progress by Phase 2022*

Metastatic Melanoma Therapeutics, Global, Clinical Trials by Trial Status, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Global, by End Point Status, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021

Metastatic Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Global, Key Sponsors, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*

List of Figures

List of Figures

Metastatic Melanoma Therapeutics, Global, Clinical Trials by Region (%), 2022*

Metastatic Melanoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*

Metastatic Melanoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2022*

Metastatic Melanoma Therapeutics Clinical Trials, North America, Top Countries (%), 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2022*

Proportion of Metastatic Melanoma to Oncology Clinical Trials, G7 Countries (%), 2022*

Metastatic Melanoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*

Metastatic Melanoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*

Proportion of Metastatic Melanoma to Oncology Clinical Trials, E7 Countries (%), 2022*

Metastatic Melanoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*

Metastatic Melanoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*

Metastatic Melanoma Therapeutics, Global, Clinical Trials by Phase (%), 2022*

Metastatic Melanoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2022*

Metastatic Melanoma Therapeutics, Global, Clinical Trials by Trial Status, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Global, by End Point Status, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021

Metastatic Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Global, Key Sponsors, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*

Metastatic Melanoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*

GlobalData Methodology

Frequently Asked Questions

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.